Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 3/20 | 0.70 |
| ▸ | F10 | P00742 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180061 | 0.85 | LSS (0.80) | LSSF10CHRM1L3MBTL1CNR1 | |
| SCHEMBL6786388 | 0.82 | LSS (0.76) | LSSF10CHRM1NPC1L3MBTL1 | |
| SCHEMBL7401658 | 0.81 | LSS (1.00) | LSSF10CHRM1L3MBTL1CNR1 | |
| SCHEMBL1387210 | 0.80 | F10 (0.82) | LSSF10CHRM1SMN1; SMN2MAPK1 | |
| SCHEMBL1387298 | 0.79 | LSS (0.88) | LSSF10CHRM1NPC1CNR1 | |
| SCHEMBL6794182 | 0.79 | F10 (0.80) | LSSF10CHRM1MAPK1 | |
| SCHEMBL6792931 | 0.79 | F10 (0.76) | LSSF10CHRM1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6181000 | 0.78 | LSS (0.76) | LSSF10CHRM1L3MBTL1CNR1 | |
| SCHEMBL1387276 | 0.78 | LSS (0.94) | LSSF10CHRM1L3MBTL1CNR1 | |
| SCHEMBL1387325 | 0.78 | F10 (0.77) | LSSF10CHRM1CNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0844877-B1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ASTRAZENECA AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| US-6090813-A | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |